Published in Rheumatology (Oxford) on September 01, 2001
CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proc Natl Acad Sci U S A (2007) 1.40
The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A (2009) 1.28
The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. Curr Opin Immunol (2011) 1.05
Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases. Arthritis (2011) 0.87
CD166 expression, characterization, and localization in salivary epithelium: implications for function during sialoadenitis. J Clin Immunol (2006) 0.80
Transgenic expression of soluble human CD5 enhances experimentally-induced autoimmune and anti-tumoral immune responses. PLoS One (2014) 0.78
Human CD6 Down-Modulation following T-Cell Activation Compromises Lymphocyte Survival and Proliferative Responses. Front Immunol (2017) 0.75
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One (2017) 0.75
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus (2003) 3.61
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Expression of the leucine operon. J Bacteriol (1966) 3.12
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) (1993) 2.88
Targeted recovery of mutations in Drosophila. Genetics (2000) 2.71
Developmentally regulated expression of chimeric genes containing muscle actin DNA sequences in transfected myogenic cells. EMBO J (1984) 2.60
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis (2010) 2.38
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Catastrophic antiphospholipid syndrome: clinical description and triggering factors in 8 patients. J Rheumatol (2000) 2.06
[Primary antiphospholipid syndrome: clinical and biological study of 36 cases]. Med Clin (Barc) (1994) 2.03
Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) (2001) 2.02
[50 years of LE cells: is it time for their retirement?]. Med Clin (Barc) (1998) 2.02
Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) (1998) 2.01
Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases. Medicine (Baltimore) (2001) 1.97
Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet (1990) 1.92
CD43 interacts with moesin and ezrin and regulates its redistribution to the uropods of T lymphocytes at the cell-cell contacts. Blood (1998) 1.91
Moesin interacts with the cytoplasmic region of intercellular adhesion molecule-3 and is redistributed to the uropod of T lymphocytes during cell polarization. J Cell Biol (1997) 1.84
Targeting of non-Ig sequences in place of the V segment by somatic hypermutation. Nature (1995) 1.80
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) (2004) 1.68
Antiphospholipid antibodies and the heart. Lessons and pitfalls for the cardiologist. Circulation (1991) 1.68
Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med (1994) 1.67
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) (1999) 1.66
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) (2007) 1.64
The clavicle hook plate for Neer type II lateral clavicle fractures. J Orthop Trauma (2009) 1.55
Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis (1998) 1.55
Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis (2004) 1.54
Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus (1997) 1.52
Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod (1993) 1.51
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother (2000) 1.51
Serotype-specific pneumococcal disease may be influenced by mannose-binding lectin deficiency. Eur Respir J (2010) 1.50
[Primary Sjögren's syndrome and lymphatic proliferation]. Med Clin (Barc) (2000) 1.47
Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med (1995) 1.47
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2011) 1.46
Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol (1999) 1.44
Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis (2005) 1.44
Transcatheter aortic valve replacement (TAVR) in patients with systemic autoimmune diseases. Lupus (2013) 1.41
[Functional abnormality of the diaphragm in the "shrinking lung" in systemic lupus erythematosus]. Rev Clin Esp (1993) 1.40
[Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions]. Rev Clin Esp (2004) 1.40
[Primary Sjögren's syndrome: clinical and immunologic study of 80 patients]. Med Clin (Barc) (1997) 1.39
Detection of plasmid-mediated quinolone resistance genes in clinical isolates of Enterobacter spp. in Spain. J Clin Microbiol (2009) 1.39
[Behcet's disease: retrospective study]. An Med Interna (2001) 1.39
[Libman-Sacks endocarditis and anticardiolipin antibodies]. Med Clin (Barc) (1989) 1.39
CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol (1999) 1.37
A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. J Immunol Methods (1995) 1.35
Polarization and interaction of adhesion molecules P-selectin glycoprotein ligand 1 and intercellular adhesion molecule 3 with moesin and ezrin in myeloid cells. Blood (2000) 1.35
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
The lung in the antiphospholipid syndrome. Ann Rheum Dis (2002) 1.33
European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus (2009) 1.28
Modulation of calcium channels of twitch skeletal muscle fibres of the frog by adrenaline and cyclic adenosine monophosphate. J Physiol (1987) 1.27
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum (2010) 1.26
Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol (1991) 1.25
Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) (2004) 1.25
Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis (2003) 1.22